Objective: Mucosal infections including vulvovaginal candidiasis are a common problem for women with human immunodeficiency virus (HIV) infection. Our objective was to determine which factors predict the development of symptomatic disease among HIV-infected women.
Materials And Methods: In a prospective study from 1991 to 1995, 205 HIV-positive women were evaluated every 6 months for occurrences of vulvovaginal candidiasis. Included in the study were all initially asymptomatic women, whether they were fungal-culture-positive or -negative at baseline. Excluded from the study were all women with symptomatic vulvovaginal candidiasis at the initial visit, those who developed trichomonas vaginitis at any visit, and those who used any antifungal agents.
Results: The risk of the development of vulvovaginal candidiasis did not differ between women who were asymptomatically colonized at baseline and those who were fungal-culture-negative. However, the risk of developing vulvovaginal candidiasis was increased 6.8 times for women with CD4 counts less than 200 cells/mm3 at baseline.
Conclusions: Fungal culture is not predictive of the development of symptomatic vulvovaginal candidiasis. Women infected with HIV who have CD4 counts below 200 cells/mm3 should be monitored more carefully for vulvovaginal candidiasis.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1784689 | PMC |
http://dx.doi.org/10.1155/S1064744900000247 | DOI Listing |
J Fungi (Basel)
December 2024
Graduate Institute of Biotechnology, National Chung Hsing University, Taichung 402, Taiwan.
Vulvovaginal candidiasis (VVC), a condition predominantly caused by , affects millions of women worldwide, prompting the need for alternative treatments due to the side effects and increasing resistance associated with conventional imidazole antifungals. This study investigated VAGINNE, a novel fermentation broth derived from species, as a potential VVC treatment. Using a BALB/c mouse model of infection, we evaluated VAGINNE's effects on vaginal microbiome composition, inflammatory markers, and tissue integrity.
View Article and Find Full Text PDFJ Fungi (Basel)
December 2024
Laboratorio de Micología Molecular, Unidad de Investigación Biomédica, Hospital Regional de Alta Especialidad de Ixtapaluca, Instituto Mexicano de Seguro Social para el Bienestar (IMSS-BIENESTAR), Carretera Federal México-Puebla Km 34.5, Ixtapaluca CP 56530, Mexico.
Vulvovaginal candidiasis (VVC) can lead to multiple complications when it occurs during pregnancy, so it is necessary to diagnose it promptly for effective treatment. Traditional methods for identifying spp. are often too time-consuming and have limited specificity and sensitivity.
View Article and Find Full Text PDFMicrobiol Spectr
January 2025
Clinical Microbiology Laboratory, "Attikon" University General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
The lack of clinical breakpoints and epidemiological cut-off values (ECOFFs) for antifungals prescribed for vulvovaginal candidiasis (VVC) make interpretation of antifungal susceptibility data difficult. This leads to empirical prescribing, poor clinical management and emergence of resistance. The susceptibilities of 152 , 105 , 31 and 8 VVC isolates against eight antifungals, were determined according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) E.
View Article and Find Full Text PDFVirulence
December 2025
Department of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, T he Netherlands.
Vulvovaginal candidiasis (VVC) is one of the most common infections caused by . VVC is characterized by an inadequate hyperinflammatory response and clinical symptoms associated with colonization of the vaginal mucosa. Compared to other host niches in which can cause infection, the vaginal environment is extremely rich in lactic acid that is produced by the vaginal microbiota.
View Article and Find Full Text PDFJ Am Acad Dermatol
January 2025
Mycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!